The target population identified for this guideline was as follows:

• Adults who are diagnosed with cancer (≥18 years of age) who have completed curative-intent treatment (e.g. adjuvant therapy for breast cancer), with no evidence of disease but continue to receive hormonal or other therapies for maintenance or cancer control or, 

• Adults (≥18) who have completed first line or primary treatment for any stage of cancer for cancer control and/or who may require intermittent treatment for cancer control or to slow disease progression but is being transitioned to post-treatment survivorship care and/or cancer monitoring or surveillance. 

This definition aligns with the definition of survivorship used in other countries, as the period after completion of initial treatment, whether the person is free from cancer and at any stage of disease (47). Treatment is defined as any modality or multimodality of therapy intended to treat cancer prescribed by a specialist and may include continuing therapies to maintain disease control (e.g., surgery, radiotherapy, chemotherapy, hormone therapy, immunotherapy, targeted). Cancer survivors receiving end of life care were excluded (defined as those with a life expectancy of 6 months or less).